Depressive DisordersAnxiety DisordersAlcohol Use Disorder (AUD)Substance Use Disorders (SUD)Palliative & End-of-Life DistressPersonality & Trait Factors

The readiness of psychiatrists to implement psychedelic-assisted psychotherapy

This pilot mixed-methods study of psychiatrists in one NHS mental health trust found widespread familiarity with and majority support for controlled therapeutic use of psychedelics, with trainees better informed than non‑training-grade psychiatrists. Despite positive attitudes, clinicians across grades reported low preparedness to deliver psychedelic-assisted psychotherapy and identified substantial training needs and wider societal and professional uncertainties as barriers to implementation.

Authors

  • Page, L.
  • Rehman, A.
  • Syed, H.

Published

Frontiers in Psychiatry
individual Study

Abstract

Introduction

Psychedelic-assisted psychotherapy is a promising approach in psychiatry; evidence is growing and it may not be long before mainstream services are expected to offer it to selected patients. This pilot study examined the attitudes and knowledge of NHS psychiatrists of all levels towards psychedelic-assisted psychotherapy and explored potential barriers and facilitators to its implementation.

Methods

A mixed-methods approach was adopted, using a cross-sectional survey and focus groups. All psychiatrists in one NHS mental health trust were approached by email to participate. The survey was analysed using a simple descriptive approach and thematic analysis was used for the focus groups.

Results

Eighty-three (25.7%) psychiatrists participated in the survey. All psychiatrists were familiar with one or more psychedelic substances. Although 77.2% felt that there should be a role for controlled or therapeutic use of psychedelics, trainees appeared better informed than non-training grade psychiatrists. Psychiatrists of all grades did not feel prepared to participate in the delivery of psychedelic-assisted psychotherapy. Thematic analysis of the focus groups identified three main themes in relation to psychedelic-assisted psychotherapy: “need for knowledge,” “openness to change,” and “uncertainty.”Discussion: NHS psychiatrists are positive about the potential for psychedelic-assisted therapy to advance psychiatric practise. However, psychiatrists are lacking in confidence or preparedness to implement this treatment should it become a mainstream option and significant training needs were identified. Thematic analysis highlighted the need for societal shifts as well as professional ones.

Available with Blossom Pro

Research Summary of 'The readiness of psychiatrists to implement psychedelic-assisted psychotherapy'

Introduction

Psychedelic-assisted psychotherapy (PAP) is emerging as a promising treatment approach in psychiatry, with growing research interest particularly for depressive disorders, cancer-related anxiety and alcohol dependence. Classical psychedelics are serotonergic hallucinogens that act via 5-HT2A receptor agonism and are increasingly framed as relatively safe, low-abuse-potential medicines with rapid therapeutic effects. Despite accumulating clinical trial evidence and regulatory attention (for example, psilocybin’s FDA “breakthrough therapy” designation in 2019), it is unclear whether the clinical workforce is prepared to provide PAP in routine services. Murnane and colleagues designed a pilot study to assess the awareness, knowledge and attitudes of National Health Service (NHS) psychiatrists towards PAP, and to identify perceived barriers and facilitators to its implementation within a nationalised healthcare system. The study focused on classic hallucinogens (LSD, psilocybin, mescaline, etc.), deliberately excluding related agents such as MDMA and ketamine, and combined a cross-sectional survey with focus groups to capture both quantitative breadth and qualitative depth of views. Secondary aims included exploring whether demographic factors such as age or training grade related to preparedness to deliver PAP.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (15)

Papers cited by this study that are also in Blossom

Psychedelics as Medicines: An Emerging New Paradigm

Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)

Psychedelic Psychiatry’s Brave New World

Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)

Psychedelics and Psychedelic-Assisted Psychotherapy

Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Show all 15 references
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)

A Survey of American Psychiatrists’ Attitudes Toward Classic Hallucinogens

Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Corrigan, K., Haran, M., Mccandliss, C. et al. · Irish Journal of Medical Science (2021)

Cited By (2)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.